Critical limb ischemia (CLI) continues to form a substantial burden on Western healthcare. Many patients still face amputation as a last treatment option. Autologous bone marrow (BM)-derived cell administration has emerged as a potential new treatment, but proof for sustainable clinical effects of BM-derived cell therapy in CLI is still lacking. The… (More)


Cite this paper

@inproceedings{ForbesClinicalTU, title={Clinical Trials Update}, author={Thomas L. Forbes and Ralf W. Sprengers and Frans L. Moll and Marianne C Verhaar} }